PMID- 25027582
OWN - NLM
STAT- MEDLINE
DCOM- 20150603
LR  - 20211021
IS  - 1432-2072 (Electronic)
IS  - 0033-3158 (Print)
IS  - 0033-3158 (Linking)
VI  - 232
IP  - 2
DP  - 2015 Jan
TI  - Antidepressant-like activity of magnesium in the olfactory bulbectomy model is 
      associated with the AMPA/BDNF pathway.
PG  - 355-67
LID - 10.1007/s00213-014-3671-6 [doi]
AB  - RATIONALE: Numerous studies suggest agents that act on glutamatergic transmission 
      as potential antidepressants. Preclinical and clinical evidence suggests that 
      magnesium, an N-methyl-D-aspartate receptor blocker, may be useful in the 
      treatment of depression. OBJECTIVE: The aim of this study was to investigate the 
      effects of magnesium on behavior; protein levels of GluN2A, GluN2B 
      [N-methyl-D-aspartate receptor (NMDAR) subunits], GluA1 [alpha-amino-3-hydroxy-5 
      methyl-4-isoxazolepropionic acid (AMPA) subunit], phospho-Ser-831-GluA1 (P-S831), 
      phospho-Ser-845-GluA1 (P-S845), and brain-derived neurotrophic factor (BDNF); and 
      messenger RNA (mRNA) levels of GluN2A and GluN2B in different brain areas in the 
      olfactory bulbectomy (OB) model of depression in rats. METHODS: Magnesium was 
      administered once daily for 14 days at three doses (10, 15, and 20 mg/kg, 
      intraperitoneal) to sham and OB rats. Following treatment, open field and passive 
      avoidance tests were performed in the sham and OB rats. After 24 h, the 
      hippocampus, the prefrontal cortex (PFC), and the amygdala of rats treated with 
      the most active dose (15 mg/kg) were harvested, and the protein and mRNA levels 
      were determined. RESULTS: Chronic administration of magnesium (15 and 20 mg/kg) 
      reduced the number of trials required to learn passive avoidance and reduced the 
      OB-induced hyperactivity. OB increased the P-S845 level in the hippocampus, which 
      was reduced by magnesium treatment. Magnesium significantly increased the levels 
      of BDNF, GluN2B, P-S831, and P-S845 protein (and mRNA) primarily in the PFC and 
      the hippocampus in OB rats. CONCLUSION: For the first time, the present results 
      demonstrate the antidepressant-like activity of magnesium in the OB animal model 
      of depression and indicate the potential involvement of the AMPA/BDNF pathway in 
      this activity.
FAU - Pochwat, Bartlomiej
AU  - Pochwat B
AD  - Department of Neurobiology, Institute of Pharmacology, Polish Academy of 
      Sciences, Smetna 12, 31-343, Krakow, Poland.
FAU - Sowa-Kucma, Magdalena
AU  - Sowa-Kucma M
FAU - Kotarska, Katarzyna
AU  - Kotarska K
FAU - Misztak, Paulina
AU  - Misztak P
FAU - Nowak, Gabriel
AU  - Nowak G
FAU - Szewczyk, Bernadeta
AU  - Szewczyk B
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20140716
PL  - Germany
TA  - Psychopharmacology (Berl)
JT  - Psychopharmacology
JID - 7608025
RN  - 0 (Antidepressive Agents)
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 0 (Receptors, AMPA)
RN  - 0 (Receptors, N-Methyl-D-Aspartate)
RN  - 1806D8D52K (Amitriptyline)
RN  - 77521-29-0 (alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid)
RN  - I38ZP9992A (Magnesium)
RN  - TFZ3H25BS1 (glutamate receptor ionotropic, AMPA 1)
SB  - IM
MH  - Amitriptyline/pharmacology
MH  - Animals
MH  - Antidepressive Agents/*pharmacology
MH  - Brain/drug effects/metabolism
MH  - Brain-Derived Neurotrophic Factor/*metabolism
MH  - Depression/drug therapy/metabolism
MH  - Disease Models, Animal
MH  - Magnesium/*pharmacology
MH  - Male
MH  - Metabolic Networks and Pathways/drug effects
MH  - Olfactory Bulb/surgery
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Receptors, AMPA/metabolism
MH  - Receptors, N-Methyl-D-Aspartate/antagonists & inhibitors/metabolism
MH  - alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid/*metabolism
PMC - PMC4297308
EDAT- 2014/07/17 06:00
MHDA- 2015/06/04 06:00
PMCR- 2014/07/16
CRDT- 2014/07/17 06:00
PHST- 2013/11/22 00:00 [received]
PHST- 2014/06/22 00:00 [accepted]
PHST- 2014/07/17 06:00 [entrez]
PHST- 2014/07/17 06:00 [pubmed]
PHST- 2015/06/04 06:00 [medline]
PHST- 2014/07/16 00:00 [pmc-release]
AID - 3671 [pii]
AID - 10.1007/s00213-014-3671-6 [doi]
PST - ppublish
SO  - Psychopharmacology (Berl). 2015 Jan;232(2):355-67. doi: 
      10.1007/s00213-014-3671-6. Epub 2014 Jul 16.